Patient, donor, and transplant characteristics
| Median age, y (range) | 5 (1-20) |
| Median weight, kg (range) | 18 (9-45) |
| Sex, male/female | 19/25 |
| Thalassemia/SCD | 33/11 |
| Pesaro class at time of CBT (only for patients with thalassemia) | |
| Class 1 | 20 (61%) |
| Class 2 | 13 (39%) |
| CMV serology | |
| Negative | 18 (41%) |
| Positive | 26 (59%) |
| ABO compatibility | |
| Matched | 27 (61%) |
| Mismatched | 17 (39%) |
| Median number of nucleated cells collected, 107/kg of recipient (range) | 5.1 (1.2-13) |
| Median number of nucleated cells infused, 107/kg of recipient (range) | 4.0 (1.2-10) |
| Conditioning | |
| SCD | |
| BU/CY | 10 |
| (associated to ATG/ALG) | 8 |
| BU/FLU/TT | 1 |
| Thalassemia | |
| BU/CY | 16 |
| (associated to ATG/ALG) | 10 |
| BU/CY/TT | 9 |
| BU/CY/FLU | 1 |
| BU/FLU/TT | 7 |
| GVHD prophylaxis | |
| CsA | 30 |
| CsA + steroids | 2 |
| CsA + MTX | 10 |
| Tacrolimus + MTX | 1 |
| MMF + MTX | 1 |
| Median age, y (range) | 5 (1-20) |
| Median weight, kg (range) | 18 (9-45) |
| Sex, male/female | 19/25 |
| Thalassemia/SCD | 33/11 |
| Pesaro class at time of CBT (only for patients with thalassemia) | |
| Class 1 | 20 (61%) |
| Class 2 | 13 (39%) |
| CMV serology | |
| Negative | 18 (41%) |
| Positive | 26 (59%) |
| ABO compatibility | |
| Matched | 27 (61%) |
| Mismatched | 17 (39%) |
| Median number of nucleated cells collected, 107/kg of recipient (range) | 5.1 (1.2-13) |
| Median number of nucleated cells infused, 107/kg of recipient (range) | 4.0 (1.2-10) |
| Conditioning | |
| SCD | |
| BU/CY | 10 |
| (associated to ATG/ALG) | 8 |
| BU/FLU/TT | 1 |
| Thalassemia | |
| BU/CY | 16 |
| (associated to ATG/ALG) | 10 |
| BU/CY/TT | 9 |
| BU/CY/FLU | 1 |
| BU/FLU/TT | 7 |
| GVHD prophylaxis | |
| CsA | 30 |
| CsA + steroids | 2 |
| CsA + MTX | 10 |
| Tacrolimus + MTX | 1 |
| MMF + MTX | 1 |
MMF indicates mycophenolate mofetil.